SAN FRANCISCO, US: Alphabet's life sciences unit Verily on Wednesday announced a study to track people for years, right down to their genetics, in a quest for insights into staying healthy.
Verily Life Sciences partnered with Duke University School of Medicine and Stanford Medicine for the Project Baseline study intended to collect broad health data from approximately 10,000 participants over the course of at least four years.
People in the study will make routine clinic visits, complete surveys, and use wrist-worn devices packed with sensors to gather biological data.
"The Project Baseline study has the opportunity to significantly influence our current body of knowledge by better understanding the indicators of wellness," American Heart Association chief executive Nancy Brown said in a statement.
"The outcome of this study could inspire a new generation of tools that are geared towards disease prevention versus just diagnosis and treatment."
Last week, Verily unveiled a wrist-worn "Study Watch" designed to gather complex health data in clinical studies.
Study Watch is meant for research and will be put to work in several studies including a multi-year study to identify patterns in the progression of Parkinson's disease, according to a blog post by Verily team members.
Environmental, genetic, and molecular information will be included in data collected in the baseline study as part of a "journey to comprehensively map human health," according to Verily.
"Currently, most of what we see as treating physicians are short snapshots in time of an individual and primarily after they are already ill," said Sanjiv Sam Gambhir, chair of radiology at Stanford Medicine and director of the Canary Centre for Cancer Early Detection.
"By focusing on the health of a broad population, we can eventually have a meaningful impact on the well-being of patients around the world."
Verily was part of the Google X laboratory known for big-vision projects such as self-driving cars and internet service delivered by high-altitude balloons, but was spun into an independent unit at Google-parent Alphabet in mid-2015.
Verily works on diabetes with the French pharmaceutical group Sanofi and has another partnership in bioelectronic medicine with the British firm GlaxoSmithKline.
I-Net Bridge For more than two decades, I-Net Bridge has been one of South Africa’s preferred electronic providers of innovative solutions, data of the highest calibre, reliable platforms and excellent supporting systems. Our products include workstations, web applications and data feeds packaged with in-depth news and powerful analytical tools empowering clients to make meaningful decisions.
We pride ourselves on our wide variety of in-house skills, encompassing multiple platforms and applications. These skills enable us to not only function as a first class facility, but also design, implement and support all our client needs at a level that confirms I-Net Bridge a leader in its field. Go to: http://www.inet.co.za
LEGAL DISCLAIMER: This Message Board accepts no liability of legal consequences that arise from the Message Boards (e.g. defamation, slander, or other such crimes). All posted messages are the sole property of their respective authors. The maintainer does retain the right to remove any message posts for whatever reasons. People that post messages to this forum are not to libel/slander nor in any other way depict a company, entity, individual(s), or service in a false light; should they do so, the legal consequences are theirs alone. Bizcommunity.com will disclose authors' IP addresses to authorities if compelled to do so by a court of law.